Jentadueto

Metformin Hydrochloride and Linagliptin, the active ingredient in Jentadueto, is a biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus, used together with diet and exercise to improve glycaemic control in adult patients.

GNH USA supplies Jentadueto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. All batches meet EU pharmacopeial standards and are shipped under controlled conditions. The product is available for bulk and individual orders.

Jentadueto is an oral antidiabetic medication used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control when combined with diet and exercise. - Inadequate control with metformin alone: adds DPP‑4 inhibition to achieve target HbA1c. - Adjunct to lifestyle therapy: used as part of a comprehensive treatment plan for adult patients.

Jentadueto may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, usually transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache. - Mild hypoglycaemia: when combined with insulin or sulfonylureas. - Metallic taste: occasional alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic failure: signs of liver dysfunction. - Renal impairment worsening: especially in patients with pre‑existing kidney disease. - Acute kidney injury: sudden decline in renal function.

Before initiating Jentadueto, clinicians should consider several safety aspects.

- Renal function assessment: evaluate eGFR and monitor periodically. - Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. - Hypoglycaemia monitoring: especially when used with insulin or sulfonylureas. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks. - Drug interaction review: check concomitant medicines that affect renal clearance or DPP‑4 activity. - Store at ambient temperature: keep in the original pack, protect from moisture.

Jentadueto can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated due to lactic acidosis risk. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Iodinated contrast agents: risk of metformin‑associated lactic acidosis; discontinue metformin before imaging.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycaemia. - Diuretics (especially thiazides): may affect renal function and metformin clearance. - Rifampin: may reduce linagliptin plasma concentrations, decreasing efficacy.